Search
  • Retail Suite Media

Pharma Dynamics launches new allergy treatment

Pharma Dynamics, an existing leader in allergy medication, has launched a revolutionary new over-the-counter product, called Nexa AllerShield™, which contains cellulose powder that literally ‘shields’ the nasal membrane of patients from nasal allergens.

“Nexa AllerShield™ is the first nasal powder spray launched into the South African market, but the product has been available abroad in more than 50 countries worldwide and is a top-seller in the US, Europe and Australia,” says Pharma Dynamics Spokesperson Nicole Jennings.

The product contains an inert natural cellulose powder of vegetable origin, called hydroxypropyl methylcellulose (HPMC). When administered, the powder acts as a barrier by coating the inside of the nasal cavity to protect against allergies caused by airborne allergens.

Allergic rhinitis is one of the most common chronic diseases globally and whilst not life-threatening, its symptoms can severely impact sufferers’ quality of life.


“Nexa AllerShield™ is a first for South Africa. It comes in the form of a powdered nasal spray and is aimed at the estimated 30 % of South Africans that suffer from nasal allergies, which is on the increase. More than 20 clinical trials prove that the product is effective in relieving symptoms such as sneezing, runny/itchy nose and eyes as well as nasal inflammation,” she says.


One such study is a randomised trial amongst 64 patients comparing the widely used nasal corticosteroid, mometasone, with Nexa AllerShield™. The treatments were found to be comparable in controlling symptoms of allergic rhinitis. The severity of sneezing, runny nose, tearing, nasal congestion, itchy eyes and scratchy throat were evaluated at the onset, 14 days and 28 days after treatment.


Nexa AllerShield™ substantially improves the rate of Nasal Mucus Clearance and PNIFR (Peak Nasal Inspiratory Flow Rate) and reduces the need for rescue medication. The efficacy of Nexa AllerShield™ is similar to that of steroidal nasal sprays in controlling symptoms of allergic rhinitis. It can therefore be used as an alternative for corticosteroids, particularly in children older than 18 months, as well as pregnant and breast-feeding women. It is also recommended as add-on treatment to antihistamine use.


During clinical trials, 85% of chronic hay fever sufferers reported a significant improvement in allergy symptoms after only three weeks of use. After a further three weeks, 90% of participants said their symptoms had vastly improved.

Nexa AllerShield™ is also non-drowsy and medicine-free, which means it can be used by children (older than 18 months) and pregnant or breast-feeding women.


Nexa is available in four variations, namely Nexa AllerShield™, Nexa Allershield Junior™, Nexa TravelShield™ and Nexa FluShield™ and are all underpinned by clinical studies.

Jennings highlights that the device has also been proven to be effective in combating viruses due to it creating a protective ‘shield’ in the nose. “It acts as a fine filter, which allows the patient to breathe normally, while trapping allergens and viruses from contact with the nasal membrane.”


In one of the trials using Nexa FluShield™, researchers noted an illness incidence decrease in 90% of patients, and the duration (in days) of upper respiratory tract infections (URTI) also decreased by 2.5 times compared to the same period in the previous year. Local experts have described Nexa as a game-changer in the way nasal allergies and congestion will be treated in South Africa going forward.


Note that Nexa AllerShield™ is not suitable for use in children under 18 months or individuals who are sensitive to cellulose and/or mint. Nexa Allershield Junior™ is not suitable for use in children under 18 months or individuals who are sensitive to cellulose and/or strawberry. Nexa TravelShield™ and Nexa FluShield™ is not suitable for children under 3 years or individuals who are sensitive to cellulose, mint or garlic.




0 views

Register 

Choose Your Preferred Publication
  • Instagram
  • Facebook
  • LinkedIn